NCT04749563View on ClinicalTrials.gov

Study of IGC-AD1 in Subjects With Dementia Due to Alzheimer's Disease

PHASE1CompletedINTERVENTIONAL

Enrollment

12

Participants

Timeline

Start Date

January 11, 2021

Primary Completion Date

June 20, 2021

Study Completion Date

June 20, 2021

Conditions

Dementia of Alzheimer Type

Interventions

DRUG

IGC AD1

IGC AD1 oral Solution

DRUG

Placebo

Placebo of IGC AD1 oral Solution

Trial Locations (1)

Unknown

Puerto Rico, San Juan

Sponsors

Lead Sponsor

IGC Pharma, LLC

All Listed Sponsors

lead

IGC Pharma, LLC

INDUSTRY

NCT04749563 - Study of IGC-AD1 in Subjects With Dementia Due to Alzheimer's Disease | Biotech Hunter | Biotech Hunter